GUIYANG XINTIAN PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.12 CNY | -2.67% |
|
-6.94% | -26.81% |
| Jun. 03 | Xintian Pharmaceutical Gets Nod to Trial Chronic Non-Bacterial Prostatitis Drug; Shares Down 3% | MT |
| May. 14 | Guiyang Xintian Pharmaceutical Co.,Ltd. Approves Cash Dividend for 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,224 | 3,339 | 2,868 | 1,995 | - | - |
| Enterprise Value (EV) 1 | 3,224 | 3,339 | 2,868 | 1,995 | 1,995 | 1,995 |
| P/E ratio | 35.1 x | 30.4 x | 37.7 x | 20.7 x | 18.2 x | 15.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 3.01 x | 1.88 x | 1.67 x | 1.49 x |
| EV / Revenue | - | - | 3.01 x | 1.88 x | 1.67 x | 1.49 x |
| EV / EBITDA | - | - | 24.8 x | 12.9 x | 11.6 x | 10.2 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | 2.64 x | 1.76 x | 1.62 x | 1.48 x |
| Nbr of stocks (in thousands) | 223,426 | 230,611 | 230,138 | 218,716 | - | - |
| Reference price 2 | 14.43 | 14.48 | 12.46 | 9.120 | 9.120 | 9.120 |
| Announcement Date | 3/25/22 | 3/27/23 | 4/11/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 954 | 1,063 | 1,192 | 1,339 |
| EBITDA 1 | - | - | 115.6 | 154.5 | 172.6 | 195.4 |
| EBIT 1 | - | - | 93.74 | 115 | 130.3 | 152.3 |
| Operating Margin | - | - | 9.83% | 10.82% | 10.93% | 11.38% |
| Earnings before Tax (EBT) 1 | - | - | 92.42 | 114.2 | 129.4 | 151.3 |
| Net income 1 | 100.6 | 116.1 | 80.87 | 100.9 | 115.5 | 133.7 |
| Net margin | - | - | 8.48% | 9.49% | 9.69% | 9.99% |
| EPS 2 | 0.4111 | 0.4762 | 0.3307 | 0.4400 | 0.5000 | 0.5800 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/25/22 | 3/27/23 | 4/11/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 7.01% | 8.4% | 8.87% | 9.38% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 4.720 | 5.180 | 5.630 | 6.160 |
| Cash Flow per Share 2 | - | - | 0.3400 | 1.040 | -0.3100 | 1.140 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/25/22 | 3/27/23 | 4/11/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
9.12
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -26.81% | 275M | |
| +19.60% | 80.67B | |
| +13.63% | 9.17B | |
| -15.14% | 4.86B | |
| +45.17% | 4.55B | |
| +15.70% | 4.34B | |
| +12.15% | 2.38B | |
| -26.13% | 2.2B | |
| +15.73% | 2.1B | |
| -40.52% | 1.86B |
- Stock Market
- Equities
- 002873 Stock
- Financials Guiyang Xintian Pharmaceutical Co.,Ltd.
